Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176720 · ClinicalTrials.gov registry record · Phase 1
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02176720: Clinical Trial Phase 1 study, sponsored by The Methodist Hospital Research Institute.
NCT02176720 is a Phase 1 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02176720, a Phase 1 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
It was previously shown that \[18F\]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.
Primary Outcome
Imaging findings will be validated by histopathology, clinical follow-up and/or repetitive imaging. If no histopathology within 3 months is available, clinical follow-up and imaging findings will be used for validation. If within 6 months of randomization no clinical progression nor progression on other imaging modalities is found, the patient will be rated as "no disease present at time of imaging".
Interventions
- DRUG FDOPA PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Why NCT02176720 stopped before completion
NCT02176720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which FDOPA PET is the first listed.
NCT02176720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02176720 about?
NCT02176720 is a clinical study titled "Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma". It was previously shown that \[18F\]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials...
What is the current status of trial NCT02176720?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-05. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02176720?
The interventions under investigation include: FDOPA PET (DRUG).
Who is sponsoring clinical trial NCT02176720?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02176720's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia